Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) rose over 5%, reaching HKD 10.62 with a trading volume of HKD 608 million, following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the development, production, and commercialization of the oral GLP-1 receptor agonist SYH2086 globally [1] Group 1 - CSPC Pharmaceutical Group has entered into an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development, production, and commercialization of SYH2086 [1] - Under the agreement, CSPC grants Madrigal exclusive rights to develop, produce, and commercialize SYH2086 worldwide while retaining rights to develop and sell other oral GLP-1 receptor agonist products in China [1] - CSPC is entitled to receive up to USD 2.075 billion in total consideration, which includes an upfront payment of USD 120 million, potential milestone payments of up to USD 1.955 billion, and high double-digit sales royalties based on annual net sales of SYH2086 [1]
石药集团涨超5% 与Madrigal订立最高20.75亿美元的独家授权协议